Not yet recruitingPhase 2NCT07055724

Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis

Studying AL amyloidosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nanjing IASO Biotechnology Co., Ltd.
Principal Investigator
Liu peng, Professor
Fudan University
Intervention
Eque-cel CAR-T Therapy(biological)
Enrollment
17 enrolled
Eligibility
18 years · All sexes
Timeline
20252027

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07055724 on ClinicalTrials.gov

Other trials for AL amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for AL amyloidosis

← Back to all trials